Growth Hormone Peptides

Stabilized GHRH(1-44) analog (TH9507)

Tesamorelin is the only FDA-approved GHRH analog, cleared in 2010 (Egrifta / Egrifta SV) for HIV-associated lipodystrophy. Unlike exogenous growth hormone, it works upstream — prompting the pituitary to release the body's own GH in its natural pulsatile pattern, which is why researchers track IGF-1 rather than GH directly. Clinical work by Falutz and Stanley documented changes in visceral and liver fat, and a small study explored effects on cognition in older adults. Outside its approved HIV indication it remains research-only with no validated protocol in general populations; the platform indexes lab-verified COAs and market pricing for every source.

CJC-1295 (no DAC) + Ipamorelin blend

CJC-1295 (no DAC / Modified GRF 1-29) and Ipamorelin are commonly marketed together as a GH-secretagogue stack. CJC-1295 (no DAC) binds the pituitary GHRH receptor and Ipamorelin selectively activates GHS-R1a without meaningful cortisol or prolactin elevation (Raun et al., 1998). GHRH + GHRP synergy for amplifying pulsatile GH release is an established concept in human physiology studies of other pairs (e.g., GHRH + GHRP-2; Veldhuis & Bowers, 2009), but the specific CJC-1295 (no DAC) + Ipamorelin combination has not been tested in a controlled human efficacy trial. Grey-market dosing (commonly 100mcg CJC-1295 + 200–300mcg Ipamorelin SubQ before bed) is not clinically validated. IMPORTANT: this blend uses CJC-1295 WITHOUT DAC only — the DAC form is a different, long-acting molecule and must not be substituted.

Growth Hormone Secretagogue Receptor Agonist (Ghrelin Mimetic)

Capromorelin is a non-peptide, orally active growth hormone secretagogue receptor 1a (GHS-R1a) agonist that mimics ghrelin to stimulate pulsatile GH release and increase appetite. A Pfizer Phase II trial in 395 adults aged 65–84 reported increased lean body mass (+1.4 kg, P=0.001), body weight (+1.4 kg, P=0.006), and improved physical function (tandem walk P=0.02, stair climb P=0.04), but the study was terminated early and no human product was ever approved. Capromorelin is FDA-approved for veterinary use (Entyce in dogs, Elura in cats) and is explicitly prohibited at all times under WADA category S2 (growth hormone secretagogues). It remains available only as a research chemical for laboratory investigation.

Steroidal SARM (Myostatin Modulator via Follistatin)

YK-11 is a synthetic steroidal selective androgen receptor modulator (SARM) — a 19-nor DHT-derived analog bearing a spiro-dioxolane modification at C-17, structurally distinct from non-steroidal SARMs such as ostarine or RAD140. In vitro, YK-11 acts as a partial androgen receptor (AR) agonist in mouse myoblasts, uniquely inducing follistatin (an endogenous myostatin antagonist) via an AR-dependent pathway, thereby indirectly inhibiting myostatin and enhancing myogenic differentiation. No human safety, tolerability, or efficacy trials exist; the only published human study administered deuterated YK-11 solely to identify urinary metabolites for anti-doping method development. YK-11 is not FDA-approved for any human use and is prohibited in competitive sport, with anti-doping laboratories actively screening for its metabolites.